EP2381942A1 - Combination therapies for neoplastic disorders - Google Patents
Combination therapies for neoplastic disordersInfo
- Publication number
- EP2381942A1 EP2381942A1 EP09789791A EP09789791A EP2381942A1 EP 2381942 A1 EP2381942 A1 EP 2381942A1 EP 09789791 A EP09789791 A EP 09789791A EP 09789791 A EP09789791 A EP 09789791A EP 2381942 A1 EP2381942 A1 EP 2381942A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- alkyl
- independently
- acyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the application is in general directed to methods of combination therapy, and combination pharmaceutical compositions.
- chemotherapeutic agents While a variety of chemotherapeutic agents are available, nearly all chemotherapeutic agents are toxic, and chemotherapy frequently causes significant, and often dangerous, side effects. Frequent side-effects include severe nausea and vomiting, bone marrow depression, immunosuppression, cytopenia (including, e.g., anemia, neutropenia, and thrombocytopenia), pain and fatigue. Additional side-effects include cachexia, mucositis, alopecia, cutaneous complications (including hypersensitivity reactions, e.g., pruritis, urticaria, and angioedema), as well as neurological, pulmonary, cardiac, reproductive and endocrine complications.
- cytopenia including, e.g., anemia, neutropenia, and thrombocytopenia
- Additional side-effects include cachexia, mucositis, alopecia, cutaneous complications (including hypersensitivity reactions, e.g., pruritis, urticaria, and angioedema), as
- Combination therapeutic approaches that permit the use of lower doses of chemotherapeutic agents than those conventionally used in monotherapy while maintaining anticancer efficacy are highly desirable.
- Such combination therapies may lead to a decrease in the frequency and/or severity of adverse side-effects and an improved quality of life for the patient.
- Further benefits of reducing the incidence of side-effects include improved patient compliance, a reduction in the number of hospitalizations needed for the treatment of adverse effects, and a decrease in the administration of analgesic agents needed to treat pain associated with the adverse effects.
- combination therapy can also maximize the therapeutic effects of chemotherapeutic agents administered at higher doses.
- chemotherapeutic agents administered at higher doses.
- such approaches may reduce the development of resistance.
- the present application provides compounds, compositions and methods of combination therapy using compounds of Formula I for the treatment of neoplastic disorders. It has been found that contacting proliferating cells with commonly used anticancer agents in combination with a compound of Formula I provides a synergistic effect on inhibiting cell proliferation.
- the application discloses a method for preventing, treating or ameliorating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
- each R 6A , R 6B , R 6D and R 8 independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 hetcroarylalkyl group, or each R 6A , R 6B , R 6D and R 8 independently is halo, CF 3 , CFN, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 ,
- Anticancer agents used in combination with the compounds of the present application may include agents selected from any of the classes known to those of ordinary skill in the art.
- Appropriate anticancer agents can include, but arc not limited to alkylating agents, antimetabolites (e.g., purine and pyrimidinc agents), plant alkaloids (e.g., vinca alkaloids) terpenoids (e.g., taxanes), topoisomerase inhibitors, anti-tumor antibiotics, hormonal therapies, and molecular targeted agents.
- Another aspect disclosed in the present application is a method for inhibiting cell proliferation in a system comprising administering to the system a compound of Formula I, as disclosed herein, and an anticancer agent or a pharmaceutically acceptable salt or ester thereof, thereby inhibiting cell proliferation.
- a further aspect disclosed in the present application is a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula I as disclosed herein, an anticancer agent and at least one pharmaceutically acceptable excipient.
- FIG. 1 is a graph of the log drug concentration against the relative fluorescent units (RFU) for Compound A and Compound B for calculation of IC50.
- FIG. 2 is a graph of the log concentration of Compound K and 5-fluorouracil against RFU for calculation of IC 50 for A375 melanoma cells.
- FIG. 3 is a bar graph showing the percent cell death for Compound K, 5-fluorouracil and the combination thereof for A375 melanoma cells.
- FIG. 4 is a graph of the log concentration of Compound K and fludarabine against RFU for calculation of IC 50 for A375 melanoma cells.
- FIG. 5 is a bar graph showing the percent cell death for Compound K, fludarabine and the combination thereof for A375 melanoma cells.
- FIG. 6 is a graph of the log concentration of Compound K and gemcitabine against RFU for calculation of IC 5 0 for A375 melanoma cells.
- FlG. 7 is a graph of the log concentration of Compound K and paclitaxel against RFU for calculation of IC 50 for A375 melanoma cells.
- FlG. 8 is a bar graph showing the percent cell death for Compound K, paclitaxel and the combination thereof for A375 melanoma cells.
- FIG. 9 is a graph of the log concentration of Compound K and sunitinib against RFU for calculation of IC 50 for A375 melanoma cells.
- FIG. 10 is a bar graph showing the percent cell death for Compound K, sunitinib and the combination thereof for A375 melanoma cells.
- FlG. 1 1 is a graph of the log concentration of Compound K and vinblastine against RFU for calculation of IC 5 0 for A375 melanoma cells.
- FIG. 12 is a bar graph showing the percent cell death for Compound K, vinblastine and the combination thereof for A375 melanoma cells.
- FIG. 13 is a graph of the log concentration of Compound K and 5-fluorouracil against RFU for calculation of IC50 for MDA-MB-468 breast cancer cells.
- FlG. 14 is a bar graph showing the percent cell death for Compound K, 5-fluorouracil and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 15 is a graph of the log concentration of Compound K and 5-fluorouracil against RFU for calculation of IC50 for MDA-MB-468 breast cancer cells.
- FIG. 16 is a bar graph showing the percent cell death for Compound K, 5-fluorouracil and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 17 is a graph of the log concentration of Compound K and cisplatin against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 18 is a bar graph showing the percent cell death for Compound K, cisplatin and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 19 is a graph of the log concentration of Compound K and cisplatin against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 20 is a bar graph showing the percent cell death for Compound K, cisplatin and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 21 is a graph of the log concentration of Compound K and doxorubicin against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 22 is a bar graph showing the percent cell death for Compound K, doxorubicin and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 23 is a graph of the log concentration of Compound K and doxorubicin against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 24 is a bar graph showing the percent cell death for Compound K, doxorubicin and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 25 is a graph of the log concentration of Compound K and gemcitabine against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 26 is a bar graph showing the percent cell death for Compound K, gemcitabine and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 27 is a graph of the log concentration of Compound K and gemcitabine against RFU for calculation of IC 50 for MDA-MB-468 breast cancer cells.
- FIG. 28 is a bar graph showing the percent cell death for Compound K, gemcitabine and the combination thereof for MDA-MB-468 breast cancer cells.
- FIG. 29 is a graph of the log concentration of Compound K and vinblastine against RFU for calculation of IC50 for MIA PaCa-2 pancreatic cancer cells.
- FIG. 30 is a bar graph showing the percent cell death for Compound K, vinblastine and the combination thereof for MIA PaCa-2 pancreatic cancer cells.
- FIG. 31 is a graph of the log concentration of Compound K and gemcitabine against RFU for calculation of IC 50 for MIA PaCa-2 pancreatic cancer cells.
- FIG. 32 is a bar graph showing the percent cell death for Compound K, gemcitabine and the combination thereof for MIA PaCa-2 pancreatic cancer cells.
- FIG. 33 is a graph of the log concentration of Compound K and sunitinib against RFU for calculation of IC 5 0 for MIA PaCa-2 pancreatic cancer cells.
- FIG. 34 is a bar graph showing the percent cell death for Compound K, sunitinib and the combination thereof for MIA PaCa-2 pancreatic cancer cells.
- FIG. 35 is a graph of the log concentration of Compound K and rapamycin against RFU for calculation of IC 50 for MIA PaCa-2 pancreatic cancer cells.
- FIG. 36 is a bar graph showing the percent cell death for Compound K, rapamycin and the combination thereof for MIA PaCa-2 pancreatic cancer cells.
- FlG. 37 is a graph of the log concentration of Compound K and 5-fluorouracil against RFU for calculation of IC 50 for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 38 is a bar graph showing the percent cell death for Compound K, 5-fluorouracil and the combination thereof for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 39 is a graph of the log concentration of Compound K and cisplatin against RFU for calculation of IC 50 for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 40 is a bar graph showing the percent cell death for Compound K, cisplatin and the combination thereof for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 41 is a graph of the log concentration of Compound K and rapamycin against RFU for calculation of IC50 for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 42 is a bar graph showing the percent cell death for Compound K, rapamycin and the combination thereof for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 43 is a graph of the log concentration of Compound K and erlotinib against RFU for calculation of IC50 for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 44 is a bar graph showing the percent cell death for Compound K, erlotinib and the combination thereof for SUM- 149PT inflammatory breast carcinoma cells.
- FIG. 45 is a graph of the log concentration of Compound K and 5-fluorouracil against RFU for calculation of IC50 for SUM-190PT inflammatory breast carcinoma cells.
- FIG. 46 is a bar graph showing the percent cell death for Compound K, 5-fluorouracil and the combination thereof for SUM- 190PT inflammatory breast carcinoma cells.
- FIG. 47 is a dose response curve for Compound K, erlotinib and the combination thereof for BT-474 breast carcinoma cells.
- FIG. 48 is a bar graph showing the percent cell death for Compound K, erlotinib and the combination thereof for BT-474 breast carcinoma cells.
- FIG. 49 is a dose response curve of Compound K and Compound K in combination with erlotinib for erlotinib-resistant MDA-MB-453 breast carcinoma cells.
- FIG. 50 is a dose response curve of erlotinib for erlotinib-resistant MDA-MB-453 breast carcinoma cells.
- FIG. 51 is a bar graph showing the percent cell death for Compound K, erlotinib and the combination thereof for erlotinib-resistant MDA-MB-453 breast carcinoma cells.
- FIG. 52 is a dose response curve of Compound K, erlotinib and a combination thereof for erlotinib-resistant T47D breast carcinoma cells.
- FIG. 53 is a bar graph showing the percent cell death for Compound K, erlotinib and the combination thereof for erlotinib-resistant T47D breast carcinoma cells.
- FIG. 54 is a dose response curve of Compound K, erlotinib and a combination thereof for erlotinib-resistant ZR-75-1 breast carcinoma cells.
- FIG. 55 is a bar graph showing the percent cell death for Compound K, erlotinib and the combination thereof for erlotinib-resistant ZR-75-1 breast carcinoma cells.
- FIG. 56 is a dose response curve of Compound K, lapatinib and a combination thereof for T47D breast carcinoma cells.
- FIG. 57 is a dose response curve of Compound K, sorafenib and a combination thereof for T47D breast carcinoma cells.
- FIG. 58 is a bar graph showing the percent cell death for Compound K, sorafenib and the combination thereof for T47D breast carcinoma cells.
- FIG. 59 is a dose response curve of Compound K, sunitinib and a combination thereof for T47D breast carcinoma cells.
- the term "subject” refers to a human or animal subject. Generally, the subject is human.
- Neoplastic disorder refers to a disorder involving aberrant cell proliferation, such as a cancer, for example.
- the cancer may result in a tumor in certain instances, and symptoms associated with a tumor sometimes are treated.
- Neoplastic disorders include, but are not limited to, abnormal cell proliferative conditions (e.g., cancer) of the hemopoietic system (e.g., white blood cell), lung, breast, prostate, kidney, pancreas, liver, heart, skeleton, colon, rectum, skin, brain, eye, lymph node, heart, testes or ovary, for example.
- abnormal cell proliferative conditions e.g., cancer
- the hemopoietic system e.g., white blood cell
- lung breast, prostate, kidney, pancreas, liver, heart, skeleton, colon, rectum, skin, brain, eye, lymph node, heart, testes or ovary, for example.
- the term "therapeutically effective amount” or “effective amount” is intended to mean that amount of a drug or pharmaceutical agent that will elicit a biological or medical response of a cell, tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- the "therapeutically effective amount” of the compound of the application may be an amount sufficient to produce an anticancer effect alone, or may be an amount sufficient to produce an anticancer effect in the presence of the additional anticancer agent.
- the amount of the additional anticancer agent may be sufficient to provide an anticancer effect alone, or may be sufficient to provide an anticancer effect in the presence of the compound of the application.
- the combination of a compound of the application and an additional anticancer agent exhibits an additive anticancer effect, such as an additive effect on inhibiting cell proliferation.
- the combination of a compound of the application and an additional anticancer agent exhibits a synergistic anticancer effect, such as a synergistic effect on inhibiting cell proliferation.
- inhibiting or reducing cell proliferation is meant to slow down, to decrease, or, for example, to stop the amount of cell proliferation, as measured using methods known to those of ordinary skill in the art, by, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100%, when compared to proliferating cells that are not subjected to the methods and compositions of the present application.
- alkyl straight-chain, brancbed-chain and cyclic monovalent hydrocarbyl radicals, and combinations of these, which contain only C and H when they are unsubstituted. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propcnyl, 3-butynyl, and the like.
- the total number of carbon atoms in each such group is sometimes described herein, e.g., when the group can contain up to ten carbon atoms it can be represented as 1 -1OC or as Cl-ClO or Cl-10.
- heteroatoms N, O and S typically
- the numbers describing the group though still written as e.g. C1-C6, represent the sum of the number of carbon atoms in the group plus the number of such heteroatoms that are included as replacements for carbon atoms in the backbone of the ring or chain being described.
- the alkyl, alkenyl and alkynyl substituents contain 1 -1OC (alkyl) or 2-lOC (alkenyl or alkynyl). Generally they contain 1 -8C (alkyl) or 2-8C (alkenyl or alkynyl). Sometimes they contain 1 -4C (alkyl) or 2-4C (alkenyl or alkynyl).
- a single group can include more than one type of multiple bond, or more than one multiple bond; such groups are included within the definition of the term "alkenyl” when they contain at least one carbon-carbon double bond, and are included within the term "alkynyl" when they contain at least one carbon-carbon triple bond.
- Alkyl, alkenyl and alkynyl groups can also be substituted by C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or C5-C10 heteroaryl, each of which can be substituted by the substituents that are appropriate for the particular group.
- Heteroalkyl “heteroalkenyl”, and “heteroalkynyl” and the like are defined similarly to the corresponding hydrocarbyl (alkyl, alkenyl and alkynyl) groups, but the 'hetero' terms refer to groups that contain 1-3 O, S or N heteroatoms or combinations thereof within the backbone residue; thus at least one carbon atom of a corresponding alkyl, alkenyl, or alkynyl group is replaced by one of the specified heteroatoms to form a heteroalkyl, heteroalkenyl, or heteroalkynyl group.
- heteroforms of alkyl, alkenyl and alkynyl groups are generally the same as for the corresponding hydrocarbyl groups, and the substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
- substituents that may be present on the heteroforms are the same as those described above for the hydrocarbyl groups.
- such groups do not include more than two contiguous heteroatoms except where an oxo group is present on N or S as in a nitro or sulfonyl group.
- alkyl as used herein includes cycloalkyl and cycloalkylalkyl groups
- cycloalkyl may be used herein to describe a carbocyclic non-aromatic group that is connected via a ring carbon atom
- cycloalkylalkyl may be used to describe a carbocyclic non-aromatic group that is connected to the molecule through an alkyl linker.
- heterocyclyl may be used to describe a non-aromatic cyclic group that contains at least one heteroatom as a ring member and that is connected to the molecule via a ring atom, which may be C or N; and “heterocyclylalkyl” may be used to describe such a group that is connected to another molecule through a linker.
- the sizes and substituents that are suitable for the cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl groups are the same as those described above for alkyl groups. As used herein, these terms also include rings that contain a double bond or two, as long as the ring is not aromatic.
- acyl encompasses groups comprising an alkyl, alkenyl, alkynyl, aryl or arylalkyl radical attached at one of the two available valence positions of a carbonyl carbon atom
- heteroacyl refers to the corresponding groups wherein at least one carbon other than the carbonyl carbon has been replaced by a heteroatom chosen from N, O and S.
- Acyl and heteroacyl groups are bonded to any group or molecule to which they are attached through the open valence of the carbonyl carbon atom. Typically, they are C1-C8 acyl groups, which include formyl, acetyl, pivaloyl, and benzoyl, and C2-C8 heteroacyl groups, which include methoxyacetyl, ethoxycarbonyl, and 4-pyridinoyl.
- the hydrocarbyl groups, aryl groups, and heteroforms of such groups that comprise an acyl or heteroacyl group can be substituted with the substituents described herein as generally suitable substituents for each of the corresponding component of the acyl or heteroacyl group.
- Aromatic moiety or "aryl” moiety refers to a monocyclic or fused bicyclic moiety having the well-known characteristics of aromaticity; examples include phenyl and naphthyl.
- heteroaryl refers to such monocyclic or fused bicyclic ring systems which contain as ring members one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings.
- Typical heteroaromatic systems include monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl and the fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C8-C10 bicyclic group such as indolyl, benzimidazolyl, indazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, pyrazolopyridyl, quinazolinyl, quinoxalinyl, cinnolinyl, and the like.
- monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidy
- any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. It also includes bicyclic groups where at least the ring which is directly attached to the remainder of the molecule has the characteristics of aromaticity.
- the ring systems typically contain 5-12 ring member atoms.
- the monocyclic heteroaryls contain 5-6 ring members, and the bicyclic heteroaryls contain 8-10 ring members.
- Aryl and heteroaryl moieties may be substituted with a variety of substituents including C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C5-C12 aryl, C1-C8 acyl, and heteroforms of these, each of which can itself be further substituted; other substituents for aryl and heteroaryl moieties include halo, OR, NR 2 , SR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN, C ⁇ CR, COOR, CONR 2 , OOCR, COR, and NO 2 , wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, C
- an arylalkyl substituent may be substituted on the aryl portion with substituents described herein as typical for aryl groups, and it may be further substituted on the alkyl portion with substituents described herein as typical or suitable for alkyl groups.
- arylalkyl and “heteroarylalkyl” refer to aromatic and heteroaromatic ring systems which are bonded to their attachment point through a linking group such as an alkylene, including substituted or unsubstituted, saturated or unsaturated, cyclic or acyclic linkers.
- the linker is C1-C8 alkyl or a hetero form thereof.
- These linkers may also include a carbonyl group, thus making them able to provide substituents as an acyl or heteroacyl moiety.
- An aryl or hctcroaryl ring in an arylalkyl or heteroarylalkyl group may be substituted with the same substituents described above for aryl groups.
- an arylalkyl group includes a phenyl ring optionally substituted with the groups defined above for aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups, where the alkyl or heteroalkyl groups can optionally cyclize to form a ring such as cyclopropane, dioxolane, or oxacyclopentane.
- a heteroarylalkyl group generally includes a C5-C6 monocyclic heteroaryl group that is optionally substituted with the groups described above as substituents typical on aryl groups and a C1-C4 alkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl groups or heteroalkyl groups, or it includes an optionally substituted phenyl ring or C5-C6 monocyclic heteroaryl and a C1-C4 heteroalkylene that is unsubstituted or is substituted with one or two C1-C4 alkyl or heteroalkyl groups, where the alkyl or heteroalkyl groups can optionally cyclize to form a ring such as cyclopropane, dioxolane, or oxacyclopentane.
- substituents may be on either the alkyl or heteroalkyl portion or on the aryl or heteroaryl portion of the group.
- the substituents optionally present on the alkyl or heteroalkyl portion are the same as those described above for alkyl groups generally; the substituents optionally present on the aryl or heteroaryl portion are the same as those described above for aryl groups generally.
- Arylalkyl groups as used herein are hydrocarbyl groups if they are unsubstituted, and are described by the total number of carbon atoms in the ring and alkylene or similar linker.
- a benzyl group is a C7-arylalkyl group
- phenylethyl is a C8-arylalkyl.
- Heteroarylalkyl refers to a moiety comprising an aryl group that is attached through a linking group, and differs from “arylalkyl” in that at least one ring atom of the aryl moiety or one atom in the linking group is a heteroatom selected from N, O and S.
- the heteroarylalkyl groups are described herein according to the total number of atoms in the ring and linker combined, and they include aryl groups linked through a heteroalkyl linker; heteroaryl groups linked through a hydrocarbyl linker such as an alkylene; and heteroaryl groups linked through a heteroalkyl linker.
- C7-heteroarylalkyl would include pyridylmethyl, phenoxy, and N-pyrrolylmethoxy.
- Alkylene refers to a divalent hydrocarbyl group; because it is divalent, it can link two other groups together. Typically it refers to -(CH 2 ) n - where n is 1-8 and often n is 1-4, though where specified, an alkylene can also be substituted by other groups, and can be of other lengths, and the open valences need not be at opposite ends of a chain. Thus -CH(Me)- and -C(Mc) 2 - may also be referred to as alkylenes, as can a cyclic group such as cyclopropan-1,1 -diyl. Where an alkylenc group is substituted, the substitucnts include those typically present on alkyl groups as described herein.
- any alkyl, alkenyl, alkynyl, acyl, or aryl or arylalkyl group or any hctcroform of one of these groups that is contained in a substitucnt may itself optionally be substituted by additional substituents.
- the nature of these substitucnts is similar to those recited with regard to the primary substituents themselves if the substitucnts arc not otherwise described.
- R 7 is alkyl
- this alkyl may optionally be substituted by the remaining substitucnts listed as embodiments for R 7 where this makes chemical sense, and where this does not undermine the size limit provided for the alkyl per se; e.g., alkyl substituted by alkyl or by alkenyl would simply extend the upper limit of carbon atoms for these embodiments, and is not included.
- each such alkyl, alkenyl, alkynyl, acyl, or aryl group may be substituted with a number of substituents according to its available valences; in particular, any of these groups may be substituted with fluorine atoms at any or all of its available valences, for example.
- Heteroform refers to a derivative of a group such as an alkyl, aryl, or acyl, wherein at least one carbon atom of the designated carbocyclic group has been replaced by a heteroatom selected from N, O and S.
- the heteroforms of alkyl, alkenyl, alkynyl, acyl, aryl, and arylalkyl are hetcroalkyl, heteroalkenyl, heteroalkynyl, heteroacyl, heteroaryl, and heteroarylalkyl, respectively. It is understood that no more than two N, O or S atoms are ordinarily connected sequentially, except where an oxo group is attached to N or S to form a nitro or sulfonyl group.
- Halo as used herein includes fluoro, chloro, bromo and iodo. Generally halo refers to fluoro or chloro.
- Amino refers to NH 2 , but where an amino is described as “substituted” or “optionally substituted”, the term includes NR'R" wherein each R' and R" is independently H, or is an alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl group or a heteroform of one of these groups, and each of the alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl groups or hcteroforms of one of these groups is optionally substituted with the substituents described herein as suitable for the corresponding group.
- R' and R" are linked together to form a 3-8 membered ring which may be saturated, unsaturated or aromatic and which contains 1-3 hcteroatoms independently selected from N, O and S as ring members, and which is optionally substituted with the substituents described as suitable for alkyl groups or, if NR'R" is an aromatic group, it is optionally substituted with the substituents described as typical for heteroaryl groups.
- carbocycle refers to a cyclic compound containing only carbon atoms in the ring, whereas a “heterocycle” refers to a cyclic compound comprising a heteroalom.
- the carbocyclic and heterocyclic structures encompass compounds having monocyclic, bicyclic or multiple ring systems.
- heteroatom refers to any atom that is not carbon or hydrogen, such as nitrogen, oxygen or sulfur.
- heterocycles include but are not limited to tetrahydrofuran, 1,3 dioxolane, 2,3 dihydrofuran, pyran, tetrahydropyran, benzofuran, isobenzofuran, 1,3 dihydro isobenzofuran, isoxazole, 4,5 dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin 2 one, pyrrole, pyridine, pyrimidine, octahydro pyrrolo[3,4 b]pyridine, piperazine, pyrazine, morpholinc, thiomorpholine, imidazole, imidazolidine 2,4 dione, 1,3 dihydrobenzimidazol 2 one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro thiophene 1,1 dioxide, diazepine, triazole, guan
- inorganic substituent refers to substituents that do not contain carbon or contain carbon bound to elements other than hydrogen (e.g., elemental carbon, carbon monoxide, carbon dioxide, and carbonate).
- inorganic substituents include but are not limited to nitro, halogen, azido, cyano, sulfonyls, sulfmyls, sulfonates, phosphates, etc.
- the terms “treat”, “treating” or “treatment” in reference to a particular disease or disorder includes prevention of the disease or disorder, and/or lessening, improving, ameliorating or abrogating the symptoms and/or pathology of the disease or disorder.
- the terms as used herein refer to ameliorating, alleviating, lessening, and removing symptoms of a disease or condition
- a candidate molecule or compound described herein may be in a therapeutically effective amount in a formulation or medicament, which is an amount that can lead to a biological effect, such as apoptosis of certain cells (e.g., cancer cells), reduction of proliferation of certain cells, or lead to ameliorating, alleviating, lessening, or removing symptoms of a disease or condition, for example.
- the terms also can refer to reducing or stopping a cell proliferation rate (e.g., slowing or halting tumor growth) or reducing the number of proliferating cancer cells (e.g., removing part or all of a tumor). These terms also are applicable to reducing a titrc of a microorganism in a system (i.e., cell, tissue, or subject) infected with a microorganism, reducing the rate of microbial propagation, reducing the number of symptoms or an effect of a symptom associated with the microbial infection, and/or removing detectable amounts of the microbe from the system.
- a system i.e., cell, tissue, or subject
- microorganism include but are not limited to virus, bacterium and fungus.
- apoptosis refers to an intrinsic cell self-destruction or suicide program.
- cells undergo a cascade of events including cell shrinkage, blebbing of cell membranes and chromatic condensation and fragmentation. These events culminate in cell conversion to clusters of membrane-bound particles (apoptotic bodies), which are thereafter engulfed by macrophages.
- polar substitucnt refers to any substituent having an electric dipole, and optionally a dipole moment (e.g., an asymmetrical polar substituent has a dipole moment and a symmetrical polar substituent does not have a dipole moment).
- Polar substituents include substituents that accept or donate a hydrogen bond, and groups that would carry at least a partial positive or negative charge in aqueous solution at physiological pH levels.
- a polar substituent is one that can accept or donate electrons in a non- covalent hydrogen bond with another chemical moiety.
- a polar substituent is selected from a carboxy, a carboxy bioisostere or other acid-derived moiety that exists predominately as an anion at a pH of about 7 to 8.
- Other polar substituents include, but are not limited to, groups containing an OH or NH, an ether oxygen, an amine nitrogen, an oxidized sulfur or nitrogen, a carbonyl, a nitrile, and a nitrogen-containing or oxygen-containing heterocyclic ring whether aromatic or non-aromatic.
- the polar substituent represented by R 3 is a carboxylate or a carboxylate bioisostere.
- Carboxylatc bioisostcrc or “carboxy bioisostere” as used herein refers to a moiety that is expected to be negatively charged to a substantial degree at physiological pH.
- the carboxylatc bioisostere is a moiety selected from the group consisting of:
- each R 7 is independently H or an optionally substituted member selected from the group consisting Of C 1-I o alkyl, C 2- Io alkenyl, C 2-1 O heteroalkyl, C 3 g carbocyclic ring, and C3.8 heterocyclic ring optionally fused to an additional optionally substituted carbocyclic or heterocyclic ring; or R 7 is a Ci. 10 alkyl, C 2 - 10 alkenyl, or C 2 - 10 heteroalkyl substituted with an optionally substituted C 3 .g carbocyclic ring or C 3 -8 heterocyclic ring.
- the polar substituent is selected from the group consisting of carboxylic acid, carboxylic ester, carboxamide, tetrazole, triazole, carboxymethanesulfonamide, oxadiazole, oxothiadiazole, thiazole, aminothiazole and hydroxythiazole.
- At least one R 8 present is a carboxylic acid or a salt, or ester or a bioisostere thereof.
- at least one R 8 present is a carboxylic acid- containing substituent or a salt, ester or bioisostere thereof.
- the R 8 substituent may be a Cl -ClO alkyl or Cl-ClO alkenyl linked to a carboxylic acid (or salt, ester or bioisostere thereof).
- anticancer agents include classic chemotherapcutic agents, as well as molecular targeted therapeutic agents, biologic therapy agents, and radiotherapeutic agents.
- Anticancer agents used in combination with the compounds of the present application may include agents selected from any of the classes known to those of ordinary skill in the art, including, for example, alkylating agents, anti-metabolites, plant alkaloids and terpenoids (e.g., taxancs), topoisomerase inhibitors, anti-tumor antibiotics, hormonal therapies, molecular targeted agents, and the like.
- an anticancer agent is an alkylating agent, an antimetabolite, a vinca alkaloid, a taxane, a topoisomerase inhibitor, an anti-tumor antibiotic, a tyrosine kinase inhibitor, or an immunosuppressive macrolide.
- Alkylating agents include (a) alkylating-like platinum-based chemotherapeutic agents such as cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, and (SP-4-3)-(cis)- amminedichloro ⁇ [2-rnethylpyridine] platinum(II); (b) alkyl sulfonates such as busulfan; (c) ethylencimine and methylmelamine derivatives such as altretaminc and thiotepa; (d) nitrogen mustards such as chlorambucil, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, trofosamidc, prcdnimustine, melphalan, and uramustine; (e) nitrosoureas such as carmustine, lomustine, fotcmustine, nimustine, ranimustine; (e
- Anti-metabolites include (a) purine analogs such as fludarabine, cladribinc, chlorodeoxyadenosine, clofarabine, mercaptopurine, pentostatin, and thioguanine; (b) pyrimidinc analogs such as fluorouracil, gemcitabine, capecitabine, cytarabine, azacitidine, edatrexate, floxuridine, and troxacitabine; (c) antifolates, such as methotrexate, pemetrexed, raltitrcxed, and trimetrexate.
- purine analogs such as fludarabine, cladribinc, chlorodeoxyadenosine, clofarabine, mercaptopurine, pentostatin, and thioguanine
- pyrimidinc analogs such as fluorouracil, gemcitabine, capecitabine, cytarabine, azacit
- Anti-metabolites also include thymidylate synthase inhibitors, such as fluorouracil, raltitrexed, capecitabine, floxuridine and pemetrexed; and ribonucleotide reductase inhibitors such as claribine, clofarabine and fludarabine.
- thymidylate synthase inhibitors such as fluorouracil, raltitrexed, capecitabine, floxuridine and pemetrexed
- ribonucleotide reductase inhibitors such as claribine, clofarabine and fludarabine.
- Plant alkaloid and terpenoid derived agents include mitotic inhibitors such as the vinca alkaloids vinblastine, vincristine, vindesine, and vinorelbine; and microtubule polymer stabilizers such as the taxanes, including, but not limited to paclitaxel, docetaxel, larotaxel, ortataxel, and tcsetaxel.
- Topoisomerase inhibitors include topoisomerase I inhibitors such as camptothccin, topotccan, irinolecan, rubitecan, and belotccan; and lopoisomcrasc Il inhibitors such as etoposidc, tcniposide, and amsacrine.
- Anti-tumor antibiotics include (a) anthracyclines such as daunorubicin (including liposomal daunorubicin), doxorubicin (including liposomal doxorubicin), epirubicin, idarubicin, and valmbicin; (b) streptomyccs-relatcd agents such as bleomycin, actinomycin, mithramycin, mitomycin, porfiromycin; and (c) anthracenediones, such as mitoxantrone and pixantronc.
- anthracyclines such as daunorubicin (including liposomal daunorubicin), doxorubicin (including liposomal doxorubicin), epirubicin, idarubicin, and valmbicin
- streptomyccs-relatcd agents such as bleomycin, actinomycin, mithramycin, mitomycin, porfiro
- Anthracyclines have three mechanisms of action: intercalating between base pairs of the DNA/RNA strand; inhibiting topoiosomerase II enzyme; and creating iron-mediated free oxygen radicals that damage the DNA and cell membranes.
- Anthracyclines are generally characterized as topoisomerase II inhibitors.
- Hormonal therapies include (a) androgens such as fluoxymesterone and testolactone; (b) antiandrogens such as bicalutamide, cyprotcrone, flutamide, and nilutamide; (c) aromatase inhibitors such as aminoglutcthimide, anastrozole, exemestane, formestane, and letrozole; (d) corticosteroids such as dexamethasone and prednisone; (e) estrogens such as diethylstilbestrol; (1) antiestrogens such as fulvestrant, raloxifene, tamoxifen, and toremifme; (g) LHRH agonists and antagonists such as buserelin, goserelin, leuprolide, and triptorelin; (h) progestins such as medroxyprogesterone acetate and mcgestrol acetate; and (i) thyroid hormones such
- Molecular targeted agents include (a) receptor tyrosine kinase ('RTK') inhibitors, such as inhibitors of EGFR, including erlotinib, gefitinib, and neratinib; inhibitors of VEGFR including vandetanib, semaxinib, and cediranib; and inhibitors of PDGFR; further included are RTK inhibitors that act at multiple receptor sites such as lapatinib, which inhibits both EGFR and HER2, as well as those inhibitors that act at of each of C-kit, PDGFR and VEGFR, including but not limited to axitinib, sunitinib, sorafenib and toceranib; also included are inhibitors of BCR-ABL, c-kit and PDGFR, such as imatinib; (b) FKBP binding agents, such as an immunosuppressive macrolide antibiotic, including rapamycin or baf ⁇ lomycin; (c) gene therapy agents, antis
- phenotype-directed therapy agents including: monoclonal antibodies such as alemtuzumab, bevacizumab, cetuximab, ibritumomab tiuxetan, rituximab, and traslxizumab; (c) immunotoxins such as gcmtuzumab ozogamicin;
- radioimmunoconjugatcs such as 131 -tositumomab
- cancer vaccines such as 131 -tositumomab
- Miscellaneous agents include altretamine, arsenic trioxide, gallium nitrate, hydroxyurea, levamisole, mitotanc, octreotide, procarbazine, suramin, thalidomide, photodynaraic compounds such as methoxsalen and sodium porfimer, and proteasome inhibitors such as bortczornib.
- Biologic therapy agents include: interferons such as interferon- ⁇ 2a and interferon- ⁇ 2b, and interlcukins such as aldesleukin, denileukin diftitox, and oprelvekin.
- combination therapies including the use of protective or adjunctive agents, including: cytoprotective agents such as armifostine, dexrazonxane, and mesna, phosphonates such as peridronate and zoledronic acid, and stimulating factors such as epoetin, darbeopetin, filgrastim, PEG-f ⁇ lgrastim, and sargramostim, arc also envisioned.
- cytoprotective agents such as armifostine, dexrazonxane, and mesna
- phosphonates such as peridronate and zoledronic acid
- stimulating factors such as epoetin, darbeopetin, filgrastim, PEG-f ⁇ lgrastim, and sargramostim, arc also envisioned.
- the application discloses a method for treating or ameliorating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
- each R 6 ⁇ , R 6B , R 6D and R 8 independently is H or an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C 1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 6A , R 6B , R 6D and R 8 independently is halo, CF 3 , CFN, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRC
- the application discloses a method for treating or ameliorating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I as described herein and an anticancer agent, or a pharmaceutically acceptable salt or ester thereof, wherein the anticancer agent is not doxorubicin.
- the application discloses a method for treating or ameliorating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 1 as described herein and an anticancer agent, or a pharmaceutically acceptable salt or ester thereof, wherein the anticancer agent is not a topoisomerase 11 inhibitor.
- the application discloses a method for treating or ameliorating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I as described herein and an anticancer agent, or a pharmaceutically acceptable salt or ester thereof, wherein the anticancer agent is not an an ti -tumor antibiotic.
- the anticancer agent is not 5-fluorouracil. In another embodiment, the anticancer agent is not a thymidylate synthase inhibitor. In yet another embodiment, the anticancer agent is not an antimetabolite pyrmidine analog. In still another embodiment, the anticancer agent is not an antimetabolite.
- the anticancer agent is not rapamycin. In another embodiment, the anticancer agent is not an immunosuppressive macro lidc antibiotic. In yet another embodiment, the anticancer agent is not FKBP binding agent.
- the anticancer agent is not erlotinib (Tarceva). In another embodiment, the anticancer agent is not a small molecule EGFR inhibitor. In yet another embodiment, the anticancer agent is not a receptor tyrosine kinase inhibitor.
- the anticancer agent is not sunitinib (Sutcnt).
- the anticancer agent is not an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a receptor tyrosine kinase inhibitor.
- the anticancer agent is not doxorubicin, 5-fluorouracil, rapamycin, erlotinib or sunitinib. In another embodiment, the anticancer agent is not any one of any four of doxorubicin, 5-fluorouracil, rapamycin, erlotinib or sunitinib. For example in one such embodiment, the anticancer agent is not 5-fluorouracil, rapamycin, erlotinib or sunitinib. In another such embodiment the anticancer agent is not doxorubicin, 5-fluorouracil, erlotinib or sunitinib.
- the anticancer agent is not any one of any three of doxorubicin, 5-fluorouracil, rapamycin, erlotinib or sunitinib.
- the anticancer agent is not 5-fluorouracil, erlotinib or sunitinib.
- the anticancer agent is not doxorubicin, erlotinib or sunitinib.
- the anticancer agent is not any one of any two of doxorubicin, 5-fluorouracil, rapamycin, erlotinib or sunitinib.
- the anticancer agent is not a topoisomerase II inhibitor, a thymidylate synthase inhibitor, an immunosuppressive macrolide antibiotic, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not any one of any four of a topoisomerase II inhibitor, a thymidylate synthase inhibitor, an immunosuppressive macrolide antibiotic, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a thymidylate synthase inhibitor, an immunosuppressive macrolide antibiotic, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a topoisomerase II inhibitor, thymidylate synthase inhibitor, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not any one of any three of a topoisomerase II inhibitor, thymidylate synthase inhibitor, an immunosuppressive macrolide antibiotic, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a topoisomerase II inhibitor, thymidylate synthase inhibitor, or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a thymidylate synthase inhibitor, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not any one of any two of a topoisomerase Il inhibitor, thymidylate synthase inhibitor, an immunosuppressive macrolide antibiotic, a small molecule EGFR inhibitor or an inhibitor of VEGFR, PDGFR and cKIT.
- the anticancer agent is not a topoisomerase II inhibitor, an antimetabolite pyrimidine analog, an FKBP binding agent, or a receptor tyrosine kinase inhibitor. In another embodiment, the anticancer agent is not any one of any three of a topoisomerase II inhibitor, an antimetabolite pyrimidine analog, an FKBP binding agent, or a receptor tyrosine kinase inhibitor. For example in one such embodiment, the anticancer agent is not a topoisomerase II inhibitor, an antimetabolite pyrimidine analog, or a receptor tyrosine kinase inhibitor.
- the anticancer agent is not an antimetabolite pyrimidine analog, an FKBP binding agent, or a receptor tyrosine kinase inhibitor. In another embodiment, the anticancer agent is not any one of any two of a topoisomerasc II inhibitor, an antimetabolite pyrimidine analog, an FKBP binding agent, or a receptor tyrosine kinase inhibitor.
- the anticancer agent used in combination with a compound of the present application is selected from 5-fluorouracil (5-FU), cisplatin, doxorubicin, fludarabine, gemeitabine, paclitaxel, rapamycin, sunitinib, crlotinib, and vinblastine.
- the anticancer agent is selected from 5-lluorouracil, cisplatin, fludarabine, gemeitabine, paclitaxel, rapamycin, sunitinib, erlotinib, and vinblastine.
- the anticancer agent is selected from cisplatin, doxorubicin, fludarabinc, gemeitabine, paclitaxel, rapamycin, sunitinib, erlotinib, and vinblastine. In still another embodiment, the anticancer agent is selected from cisplatin, fludarabine, gemeitabine, paclitaxel, rapamycin, sunitinib, erlotinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, doxorubicin, fludarabine, gemeitabine, paclitaxel, sunitinib, erlotinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, fludarabine, gemeitabine, paclitaxel, sunitinib, erlotinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, doxorubicin, fludarabine, gemeitabine, paclitaxel, rapamycin, sunitinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, fludarabinc, gemeitabine, paclitaxel, rapamycin, sunitinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, doxorubicin, fludarabine, gemeitabine, paclitaxel, rapamycin, erlotinib, and vinblastine.
- the anticancer agent is selected from 5-fluorouracil, cisplatin, fludarabine, gemeitabine, paclitaxel, rapamycin, erlotinib, and vinblastine.
- the anticancer agent used in combination with a compound of the present application is selected from doxorubicin, cisplatin, fludarabine, gemeitabine, paclitaxel, and vinblastine.
- the anticancer agent used in combination with a compound of the present application is selected from cisplatin, fludarabine, gemeitabine, paclitaxel, and vinblastine.
- the compound of Formula I lias the structure of Formula II, III, IV, V or VI:
- each R 6 ⁇ and R 8 independently is H or an optionally substituted C1-C8 alkyl, C2-C8 hetcroalkyl, C2-C8 alkcnyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, or each R 6A and R 8 independently is halo, CF 3 , CFN, OR, NR 2 , NROR, NRNR 2 , SR, SOR, SO 2 R, SO 2 NR 2 , NRSO 2 R, NRCONR 2 , NRCOOR, NRCOR, CN,
- the compound of Formula I is a compound (Compound K) having the formula:
- the compound of formula 1 is a compound having formula (1 ) or (2):
- Compounds of Formulae I, II, 111, IV, V, and VI can exert biological activities that include, but are not limited to, inhibiting cell proliferation and modulating protein kinase activity.
- Compounds of such Formulae can modulate CK2 activity, for example.
- Such compounds therefore can be utilized in multiple applications by a person of ordinary skill in the art.
- compounds described herein may find uses that include, but are not limited to, (i) modulation of protein kinase activity (e.g., CK2 activity), (ii) modulation of cell proliferation, (iii) modulation of apoptosis, and (iv) treatment of cell proliferation related disorders, such as neoplastic disorders, when administered alone or in combination with another anticancer agent.
- the application discloses a method for inhibiting or slowing cell proliferation in a system, comprising administering to said system an effective amount of a compound of Formula I, II, III, IV, V, or VI, as described herein, or a pharmaceutically acceptable salt or ester thereof, and an anticancer agent or a pharmaceutically acceptable salt or ester thereof; thereby inhibiting or slowing cell proliferation.
- the system may be a cell, tissue or subject.
- the present application also discloses methods for preventing, treating or ameliorating neoplastic disorders, as well as for inhibiting or slowing cell proliferation, comprising the administration of a therapeutically effective amount of a compound (Compound K) having the formula:
- compositions comprising a compound of Formula I, II, III, IV, V or VI, or a pharmaceutically acceptable salt or ester thereof, and a commonly used anticancer agent, or a pharmaceutically acceptable salt or ester thereof, and at least one pharmaceutically acceptable excipient.
- the combination is administered in an amount effective to inhibit cell proliferation.
- the present application further discloses pharmaceutical compositions comprising a compound of the application or a pharmaceutically acceptable salt or ester thereof, and a commonly used anticancer agent, or a pharmaceutically acceptable salt or ester thereof, and at least one pharmaceutically acceptable excipient.
- the combination is administered in an amount effective to inhibit cell proliferation.
- the compound of the application is Compound K, Compound 1, or Compound 2, or a salt or ester thereof.
- the combination therapy is administered to individuals who have a neoplastic disorder.
- the combination therapy is administered to individuals who do not yet show clinical signs of a neoplastic disorder, but who are at risk of developing a neoplastic disorder.
- the present application discloses methods for preventing or reducing the risk of developing a neoplastic disorder.
- a single pharmaceutical dosage formulation that contains both a compound of the application, such as Compound K, and the anticancer agent is administered.
- the compound and the anticancer agent may be, for example, administered at essentially the same time, for example, concurrently, or at separately staggered times, for example, sequentially.
- the individual components of the combination may be administered separately, at different times during the course of therapy, or concurrently, in divided or single combination forms.
- the present application discloses, for example, simultaneous, staggered, or alternating treatment.
- the compound of the application may be administered at the same time as an anticancer agent, in the same pharmaceutical composition; the compound of the application may be administered at the same time as the anticancer agent, in separate pharmaceutical compositions; the compound of the application may be administered before the anticancer agent, or the anticancer agent may be administered before the compound of the application, for example, with a time difference of seconds, minutes, hours, days, or weeks.
- a staggered treatment a course of therapy with the compound of the application may be administered, followed by a course of therapy with the anticancer agent, or the reverse order of treatment may be used, more than one nests of treatments with each component may be used.
- one component for example, the compound of the application or the anticancer agent
- Compound K may be administered while the anticancer agent or its derivative products remains in the bloodstream, or the anticancer agent may be administered while Compound K or its derivatives remains in the bloodstream.
- the second component is administered after all, or most of the first component, or its derivatives, have left the bloodstream of the mammal.
- Anticancer agents used in combination with the compounds of the present application may include agents selected from any of the classes known to those of ordinary skill in the art.
- Appropriate anticancer agents can include, but are not limited to alkylating agents, antimetabolites (e.g., purine and pyrimidine agents), plant alkaloids (e.g., vinca alkaloids) terpenoids (e.g., taxanes), topoisomerase inhibitors, anti-tumor antibiotics, hormonal therapies, and molecular targeted agents, such as receptor tyrosine kinase (RTK) inhibitors (e.g., PDGFR, VEFGR, EGFR inhibitors) and monoclonal antibodies, among others.
- RTK receptor tyrosine kinase
- compositions and methods of the present application will typically be used in therapy for human patients, they may also be used in veterinary medicine to treat similar or identical diseases.
- the compositions may, for example, be used to treat mammals, including, but not limited to, primates and domesticated mammals.
- the compositions may, for example be used to treat herbivores.
- the compositions of the present application include geometric and optical isomers of one or more of the drugs, wherein each drug is a racemic mixture of isomers or one or more purified isomers.
- compositions suitable for use in the present application include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- the compounds of the present application may exist as pharmaceutically acceptable salts.
- pharmaceutically acceptable salts is meant to include salts of active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituent moieties found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Included are base addition salts such as sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids, for example, acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19).
- Certain specific compounds of the present application contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Examples of applicable salt forms include hydrochlorides, hydrobromidcs, sulfates, methanesulfonatcs, nitrates, maleates, acetates, citrates, fumarates, tartrates (eg (+)-tartrates, (-)-tartratcs or mixtures thereof, including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid.
- These salts may be prepared by methods known to those skilled in art.
- the neutral forms of the compounds are typically regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- esters in the present application refer to non-toxic esters, generally the alkyl esters are methyl, ethyl, propyl, isopropyl, butyl, isobutyl or pentyl esters, more often the alkyl ester is methyl ester. However, other esters such as phenyl-Ci-5 alkyl may be employed if desired. Ester derivatives of certain compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
- Certain compounds of the present application can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present application. Certain compounds of the present application may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present application and are intended to be within the scope of the present application.
- a physiologically acceptable carrier is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
- physiologically acceptable carriers include, but are not limited to, water, saline, physiologically buffered saline.
- Certain compounds of the present application possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present application. Therefore, single stereochemical isomers as well as enantiomeric and diastercomeric mixtures of the present compounds arc within the scope of the application.
- the compounds of the present application do not include those which are known in art to be too unstable to synthesize and/or isolate.
- Optically active (R)- and (S)-, or (D)- and (L)-isomcrs may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. It will be apparent to one skilled in the art that certain compounds of this application may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the application.
- structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of this application.
- the compounds of the present application may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present application, whether radioactive or not, are encompassed within the scope of the present disclosure.
- the present application provides compounds that are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present application.
- prodrugs can be converted to the compounds of the present application by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present application when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- the descriptions of compounds of the present application are limited by principles of chemical bonding known to those skilled in the art.
- a group may be substituted by one or more of a number of substituents
- substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions.
- a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring hcteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
- a compound of the present application can be formulated as a pharmaceutical composition. Such a pharmaceutical composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such, as transdermal patches or iontophoresis devices.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
- Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.; 1975.
- Other examples of drug formulations can be found in Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.
- Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable dilutent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that arc sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
- Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules.
- the compounds of this application are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
- a contemplated aromatic sulfone hydroximate inhibitor compound can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
- Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
- the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.
- formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
- a contemplated aromatic sulfone hydroximate inhibitor compound can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
- Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
- Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
- the amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.
- the dosage regimen utilizing the compounds of the present application in combination with an anticancer agent is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt or ester thereof employed. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective dosage amounts to be given to a person in need of the instant combination therapy.
- Three-thousand (3000) cells are plated per well in each well of two 96 well plates (duplicates). Cells are incubated overnight at 37 degrees C. The following day, one or more of the compounds are added to the plates, and concentrations of each of the compounds are systematically varied across the plates. Typically, one compound is varied vertically using two, three or four-fold dilutions and the second compound is varied horizontally using two, three or four-fold dilutions across each plate (shown hereafter).
- the top concentration for Compound K is 100, 30 or 10 micromolar.
- the top concentration for other drugs, such as rapamycin or cisplatin varies between 200 micromolar and 30 nanomolar.
- synergy is affected by the order of addition of the two compounds.
- the first drug was added one day prior to the second.
- the analysis is performed with Alamar Blue cell viability.
- twenty microliters of AlamarBlue reagent (Invitrogen, Carlsbad CA) was added per well. The plates were incubated for four hours at 37 degrees Celsius and the resulting fluorescence was measured at Ex 560 nm/ Em 590 nm.
- Example Ia Calculating IC50s for single agents
- a percent inhibition is calculated for every well in the plate based on the response data gathered as stated in Example 1.
- the concentration of Compound K increases regularly as the row number increases from 1 to 8 .
- the high concentration e.g. 100 micromolar
- the concentration of drug increases regularly as the column letter increases from A to L (as noted in the table below).
- the high concentration e.g. 30 micromolar
- a representative plate utilized for the studies is shown hereafter.
- the expected percent inhibition value is derived by assuming exact additivity between the effect of Compound K and the added drug. Hence the expected value for any well of interest is calculated as the percent inhibition observed for Compound K alone at the same concentration present in that well multiplied by the percent inhibition observed for the added drug alone at the same concentration present in that well. In practice this means the percent inhibition observed for Compound K comes from column A as the concentration of the added drug is 0 here. Similarly, the percent inhibition observed for added drug comes from row 2 (as the concentration of Compound K is 0 here) e.g. the expected value for well D8 is obtained by multiplying the percent inhibition observed in well A8 by the percent inhibition observed in well D2.
- Controls for these studies are the dose response curves for each of the two drugs by themselves. Such controls allow one to predict the cytotoxicity for each possible combination for each of the two drugs based simply on adding the cytotoxicity observed for each of the two drugs when used alone.
- Combination index provides quantitative measure of the extent of drug interactions CI ⁇ [ ⁇ ]/IC50 ⁇ +[B]/IC50B, where IC50 A and IC50 B concentrations of singe agents to achieve 50% effect alone and [A] and [B] concentrations of these two agents to achieve 50% effect in combination.
- a CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism respectively.
- IC50s that were determined with Sigmoidal dose-response (variable slope) using GraphPad Prism Software. The value of 50% effect was calculated as a half of an average between the Top value for compound K and combination compound. CI value is calculated at the lowest drug concentrations at which the 50% effect was achieved.
- Example 3 5-Fluorouracil/Compound K combination testing in A375 melanoma cells
- 5-Fluorouracil thymidylate synthase inhibitor
- 5-Fluorouracil was added first, Compound K the next day (5 day assay in total). Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism. The experiment was performed in duplicate. Both data sets are presented.
- Fludarabine was added first, Compound K the next day (4 day assay in total). Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism. The experiment was performed in duplicate. Both data sets are presented.
- Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism.
- the experiment was performed in duplicate. Both data sets are presented.
- Example 6 Paclitaxcl/Compound K. combination testing in A375 melanoma cells
- Paclitaxel a mitotic inhibitor
- Paclitaxel was tested in combination with Compound K in the melanoma cell line A375.
- Paclitaxel was added 24 hours before Compound K in a 5 day assay.
- Paclitaxel was added first, Compound K the next day (5 day assay in total). Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism. The experiment was performed in duplicate.
- Example 7 Sunitinib/Compound K combination testing in A375 melanoma cells [00205] Sunitinib, a multi tyrosine-kinase inhibitor, was tested in combination with
- Example 8 Vinblastine/Compound K combination testing in A375 melanoma cells
- Vinblastine a mitotic inhibitor
- Example 11 Doxorubicin/Compound K combination testing in MDA-MB-468 breast cancer cells
- Example 12 Gemcitabine/Compound K combination testing in MDA-MB-468 breast cancer cells
- Example 13 Vinblastine/Compound K combination testing in MIA PaCa-2 pancreatic cancer cells
- Vinblastine a mitotic inhibitor
- Gcmcitabine a pyrimidine analog
- Example 15 Sunitinib/Compound K combination testing in MIA PaCa-2 pancreatic cancer cells
- Rapamycin an immunosuppressive macrolidc
- MlA PaCa-2 pancreatic cancer cell line
- Rapamycin and Compound K are added simultaneously (4 day assay in total) .
- Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism. The experiment was performed in duplicate. Both data sets are presented.
- Example 17 5-Fluorouracil/Compound K combination testing in SUM- 149PT inflammatory breast carcinoma cells
- 5-Fluorouracil a pyrimidine analog
- SUM-149PT a pyrimidine analog
- Example 18 Cisplatin/Compound K combination testing in SUM- 149PT inflammatory breast carcinoma cells
- Cisplatin was added first, Compound K the next day (5 day assay in total) .
- Results indicate the degree of inhibitory effect found with agent combination, where a positive value denotes synergy and a negative value antagonism. The experiment was performed in duplicate. Both data sets are presented.
- Rapamycin an immunosuppressive macrolide
- Erlotinib a small molecule EGFR inhibitor
- SUM-149PT a small molecule EGFR inhibitor
- Example 22 Erlotinib/Compound K combination testing in erlotinib-scnsitivc BT-474 breast carcinoma cells
- Erlotinib a small molecule EGFR inhibitor
- Erlotinib was added simultaneously with Compound K in 1:1 ratio in a 4 day assay. The experiment was performed in triplicate. The dose-response curves for single agents and combination are presented.
- Example 23 Erlotinib/Compound K combination testing in erlotinib-resistant MDA-MB-453 breast carcinoma cells
- Erlotinib a small molecule EGFR inhibitor
- MDA-MB453 breast carcinoma cell line
- Example 24 Brlotinib/Cornpound K combination testing in crlotinib-rcsistant T47D breast carcinoma cells
- Example 25 Erlotinib/Compound K combination testing in erlotinib-resistant ZR-75-1 breast carcinoma cells
- Example 26 Lapatinib/Compound K combination testing in T47D breast carcinoma cells [00358J Lapatinib, a small molecule EGFR/Her2 inhibitor, was tested in combination with
- Example 27 Sorafenib/Compound K combination testing in T47D breast carcinoma cells
- Sorafenib a small molecule Raf/PDGFR/VEGFR2/VEGFR3/cKit inhibitor
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14328209P | 2009-01-08 | 2009-01-08 | |
PCT/US2009/046948 WO2010080170A1 (en) | 2009-01-08 | 2009-06-10 | Combination therapies for neoplastic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2381942A1 true EP2381942A1 (en) | 2011-11-02 |
Family
ID=40973134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09789791A Withdrawn EP2381942A1 (en) | 2009-01-08 | 2009-06-10 | Combination therapies for neoplastic disorders |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2381942A1 (ko) |
JP (1) | JP2012514638A (ko) |
KR (1) | KR20110116153A (ko) |
CN (1) | CN102341107A (ko) |
AU (1) | AU2009336141A1 (ko) |
BR (1) | BRPI0924041A2 (ko) |
CA (1) | CA2749261A1 (ko) |
IL (1) | IL213969A0 (ko) |
MX (1) | MX2011007384A (ko) |
RU (1) | RU2011133093A (ko) |
SG (1) | SG172922A1 (ko) |
WO (1) | WO2010080170A1 (ko) |
ZA (1) | ZA201105755B (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
AU2019362050A1 (en) * | 2018-10-19 | 2021-05-13 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
CN114869903A (zh) * | 2022-06-14 | 2022-08-09 | 苏天生命科技(苏州)有限公司 | 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009002298A (es) * | 2006-09-01 | 2009-06-04 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteina quinasa y de parp. |
WO2008127707A1 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
-
2009
- 2009-06-10 WO PCT/US2009/046948 patent/WO2010080170A1/en active Application Filing
- 2009-06-10 EP EP09789791A patent/EP2381942A1/en not_active Withdrawn
- 2009-06-10 KR KR1020117018286A patent/KR20110116153A/ko not_active Application Discontinuation
- 2009-06-10 AU AU2009336141A patent/AU2009336141A1/en not_active Abandoned
- 2009-06-10 MX MX2011007384A patent/MX2011007384A/es not_active Application Discontinuation
- 2009-06-10 JP JP2011545342A patent/JP2012514638A/ja not_active Withdrawn
- 2009-06-10 CN CN2009801578849A patent/CN102341107A/zh active Pending
- 2009-06-10 SG SG2011050051A patent/SG172922A1/en unknown
- 2009-06-10 CA CA2749261A patent/CA2749261A1/en not_active Abandoned
- 2009-06-10 BR BRPI0924041A patent/BRPI0924041A2/pt not_active IP Right Cessation
- 2009-06-10 RU RU2011133093/15A patent/RU2011133093A/ru not_active Application Discontinuation
-
2011
- 2011-07-07 IL IL213969A patent/IL213969A0/en unknown
- 2011-08-04 ZA ZA2011/05755A patent/ZA201105755B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2010080170A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2012514638A (ja) | 2012-06-28 |
SG172922A1 (en) | 2011-08-29 |
CA2749261A1 (en) | 2010-07-15 |
KR20110116153A (ko) | 2011-10-25 |
MX2011007384A (es) | 2011-12-14 |
WO2010080170A1 (en) | 2010-07-15 |
CN102341107A (zh) | 2012-02-01 |
BRPI0924041A2 (pt) | 2016-01-26 |
IL213969A0 (en) | 2011-08-31 |
RU2011133093A (ru) | 2013-02-20 |
ZA201105755B (en) | 2012-04-25 |
AU2009336141A1 (en) | 2011-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100173013A1 (en) | Treatment of neoplastic disorders using combination therapies | |
EP3237418B1 (en) | Triazolopyrimidine compounds and uses thereof | |
EP3423443B1 (en) | Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors | |
ES2726717T3 (es) | Imidazopiridinas sustituidas con isoxazolilo | |
US20160074409A1 (en) | Treatment of Skeletal-Related Disorders | |
US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
EP2575969B1 (en) | Antiviral activity of bicyclic heterocycles | |
WO2015011084A1 (de) | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen | |
DE69717148T2 (de) | 3-pyridylenantiomere und ihre verwendung als analgetika | |
CN111494386A (zh) | 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤 | |
WO2014042433A2 (en) | Compounds and compositions for modulating adenosine a3 receptor activity | |
JP2017528475A (ja) | Rafキナーゼ阻害剤としての化合物および組成物 | |
MX2008013089A (es) | Uso de compuestos de imidazo[2,1-b]-1,3,4-tiadiazole-2-sulfonamida para tratar dolor neuropatico. | |
WO2018234978A1 (en) | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | |
AU2020337350A1 (en) | Triazolopyrimidines as A2A / A2B inhibitors | |
KR20120044281A (ko) | 단백질 키나제 ck2 활성과 관련된 장애의 치료 방법 | |
WO2011029832A1 (de) | Neue thiazol- und oxazol-hepcidin-antagonisten | |
TW202321219A (zh) | 雜環衍生物及其組合物和藥學上的應用 | |
US20120015969A1 (en) | Novel aminopyridine derivatives having aurora a selective inhibitory action | |
EP2381942A1 (en) | Combination therapies for neoplastic disorders | |
TW202222311A (zh) | 結合熱休克蛋白90(hsp90)之共軛體和彼之調製劑 | |
JP7329509B2 (ja) | 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤 | |
WO2020198067A1 (en) | Pkm2 modulators and methods for their use | |
AU2016341884B2 (en) | Piperazinyl norbenzomorphan compounds and methods for using the same | |
RU2530887C2 (ru) | Соединения хиназолина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110729 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20131203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140103 |